OPTUS Pharmaceutical Co., Ltd. (KOSDAQ:131030)
South Korea · Delayed Price · Currency is KRW 10,800
-2,970 (-21.57%)
At close: Apr 2, 2026
OPTUS Pharmaceutical Revenue
In the year 2025, OPTUS Pharmaceutical had annual revenue of 87.16B KRW with 6.42% growth. OPTUS Pharmaceutical had revenue of 22.56B in the quarter ending December 31, 2025, a decrease of -1.81%.
Revenue
87.16B
Revenue Growth
+6.42%
P/S Ratio
2.19
Revenue / Employee
548.18M
Employees
159
Market Cap
190.58B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 87.16B | 5.26B | 6.42% |
| Dec 31, 2024 | 81.90B | 9.48B | 13.09% |
| Dec 31, 2023 | 72.43B | 13.77B | 23.47% |
| Dec 31, 2022 | 58.66B | 1.34B | 2.34% |
| Dec 31, 2021 | 57.32B | -3.51B | -5.77% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NOVAREX | 404.26B |
| DongKoo Bio & Pharma | 242.69B |
| Kyung Dong Pharmaceutical | 196.27B |
| GREEN CROSS WellBeing | 164.68B |
| DAE HWA Pharmaceutical | 143.06B |
| HYUNDAI BIOLAND | 130.51B |
| KOREA PHARMA | 87.60B |
| High Tech Pharm | 70.18B |